Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARγ2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures

Xudong Li, Quanjun Cui, Chinghai Kao, Gwo Jaw Wang, Gary Balian

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

The mechanism whereby lovastatin can counteract steroid-induced osteonecrosis and osteoporosis is poorly understood. We assessed the effect of lovastatin on a multipotential cell line, D1, which is capable of differentiating into either the osteoblast or the adipocyte lineage. The expression of bone cell and fat cell transcription factors Cbfa1/Runx2 and PPARγ2, respectively, were determined. 422aP2 gene expression was analyzed. Osteocalcin promoter activity was measured by cotransfecting the cells with the phOC-luc and pSV β-Gal plasmids. Lovastatin enhanced osteoblast differentiation as assessed by a 1.8× increase in expression of Cbfa1/Runx2 and by a 5× increase in osteocalcin promoter activity. Expression of PPARγ2 was decreased by 60%. By enhancing osteoblast gene expression and by inhibiting adipogenesis, lovastatin may shunt uncommitted osteoprogenitor cells in marrow from the adipocytic to the osteoblastic differentiation pathway. Future evaluation of lovastatin and other lipid-lowering drugs will help determine their potential as therapeutic agents for osteonecrosis and osteoporosis.

Original languageEnglish
Pages (from-to)652-659
Number of pages8
JournalBone
Volume33
Issue number4
DOIs
StatePublished - Oct 1 2003

Fingerprint

Lovastatin
Bone Marrow Cells
Cell Culture Techniques
Osteoblasts
Osteonecrosis
Osteocalcin
Adipocytes
Osteoporosis
Gene Expression
Adipogenesis
Plasmids
Transcription Factors
Bone Marrow
Steroids
Lipids
Bone and Bones
Cell Line
Pharmaceutical Preparations

Keywords

  • Adipocyte
  • Mesenchymal cells
  • Osteoblast
  • Statins
  • Transcriptional Factors

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARγ2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. / Li, Xudong; Cui, Quanjun; Kao, Chinghai; Wang, Gwo Jaw; Balian, Gary.

In: Bone, Vol. 33, No. 4, 01.10.2003, p. 652-659.

Research output: Contribution to journalArticle

@article{5560f9fe445d4041a4ce6cb9f44cf107,
title = "Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARγ2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures",
abstract = "The mechanism whereby lovastatin can counteract steroid-induced osteonecrosis and osteoporosis is poorly understood. We assessed the effect of lovastatin on a multipotential cell line, D1, which is capable of differentiating into either the osteoblast or the adipocyte lineage. The expression of bone cell and fat cell transcription factors Cbfa1/Runx2 and PPARγ2, respectively, were determined. 422aP2 gene expression was analyzed. Osteocalcin promoter activity was measured by cotransfecting the cells with the phOC-luc and pSV β-Gal plasmids. Lovastatin enhanced osteoblast differentiation as assessed by a 1.8× increase in expression of Cbfa1/Runx2 and by a 5× increase in osteocalcin promoter activity. Expression of PPARγ2 was decreased by 60{\%}. By enhancing osteoblast gene expression and by inhibiting adipogenesis, lovastatin may shunt uncommitted osteoprogenitor cells in marrow from the adipocytic to the osteoblastic differentiation pathway. Future evaluation of lovastatin and other lipid-lowering drugs will help determine their potential as therapeutic agents for osteonecrosis and osteoporosis.",
keywords = "Adipocyte, Mesenchymal cells, Osteoblast, Statins, Transcriptional Factors",
author = "Xudong Li and Quanjun Cui and Chinghai Kao and Wang, {Gwo Jaw} and Gary Balian",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S8756-3282(03)00239-4",
language = "English",
volume = "33",
pages = "652--659",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARγ2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures

AU - Li, Xudong

AU - Cui, Quanjun

AU - Kao, Chinghai

AU - Wang, Gwo Jaw

AU - Balian, Gary

PY - 2003/10/1

Y1 - 2003/10/1

N2 - The mechanism whereby lovastatin can counteract steroid-induced osteonecrosis and osteoporosis is poorly understood. We assessed the effect of lovastatin on a multipotential cell line, D1, which is capable of differentiating into either the osteoblast or the adipocyte lineage. The expression of bone cell and fat cell transcription factors Cbfa1/Runx2 and PPARγ2, respectively, were determined. 422aP2 gene expression was analyzed. Osteocalcin promoter activity was measured by cotransfecting the cells with the phOC-luc and pSV β-Gal plasmids. Lovastatin enhanced osteoblast differentiation as assessed by a 1.8× increase in expression of Cbfa1/Runx2 and by a 5× increase in osteocalcin promoter activity. Expression of PPARγ2 was decreased by 60%. By enhancing osteoblast gene expression and by inhibiting adipogenesis, lovastatin may shunt uncommitted osteoprogenitor cells in marrow from the adipocytic to the osteoblastic differentiation pathway. Future evaluation of lovastatin and other lipid-lowering drugs will help determine their potential as therapeutic agents for osteonecrosis and osteoporosis.

AB - The mechanism whereby lovastatin can counteract steroid-induced osteonecrosis and osteoporosis is poorly understood. We assessed the effect of lovastatin on a multipotential cell line, D1, which is capable of differentiating into either the osteoblast or the adipocyte lineage. The expression of bone cell and fat cell transcription factors Cbfa1/Runx2 and PPARγ2, respectively, were determined. 422aP2 gene expression was analyzed. Osteocalcin promoter activity was measured by cotransfecting the cells with the phOC-luc and pSV β-Gal plasmids. Lovastatin enhanced osteoblast differentiation as assessed by a 1.8× increase in expression of Cbfa1/Runx2 and by a 5× increase in osteocalcin promoter activity. Expression of PPARγ2 was decreased by 60%. By enhancing osteoblast gene expression and by inhibiting adipogenesis, lovastatin may shunt uncommitted osteoprogenitor cells in marrow from the adipocytic to the osteoblastic differentiation pathway. Future evaluation of lovastatin and other lipid-lowering drugs will help determine their potential as therapeutic agents for osteonecrosis and osteoporosis.

KW - Adipocyte

KW - Mesenchymal cells

KW - Osteoblast

KW - Statins

KW - Transcriptional Factors

UR - http://www.scopus.com/inward/record.url?scp=0141750651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141750651&partnerID=8YFLogxK

U2 - 10.1016/S8756-3282(03)00239-4

DO - 10.1016/S8756-3282(03)00239-4

M3 - Article

VL - 33

SP - 652

EP - 659

JO - Bone

JF - Bone

SN - 8756-3282

IS - 4

ER -